文献速递生殖医学母胎医学

POU5F1 CRISPR/Cas9靶向小鼠与人类植入前发育的比较分析揭示种间差异

Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences.
PubMed 文献 · Hum Reprod · 2021-01-01

该研究比较了CRISPR/Cas9靶向POU5F1后小鼠与人类植入前胚胎的发育能力。小鼠中优化方法后编辑效率高,但敲除胚胎囊胚形成率显著降低且缺乏内细胞团(ICM);人类IVM卵母细胞注射后编辑效率达88.37%,胚胎从八细胞期起发育受损,仅4.55%到达晚期囊胚且完全无ICM。

要点

  • POU5F1敲除导致小鼠和人类胚胎囊胚形成率显著下降且缺乏ICM。
  • 人类IVM卵母细胞M期注射编辑效率88.37%,但仅4.55%发育至晚期囊胚。
  • POU5F1缺失伴随SOX17表达缺失,种间保守。

核心结论

  • POU5F1是小鼠和人类胚胎发育至囊胚阶段所必需的,敲除胚胎囊胚形成率显著降低且缺乏内细胞团。

研究设计与样本

  • 研究首先在小鼠B6D2F1和B6CBA品系中优化CRISPR-Cas9递送方法,比较S期注射(n=135)与M期注射(n=23),并设置多个对照组。
  • 优化方法应用于人类IVM卵母细胞(n=101),对照组为ICSI IVM卵母细胞(n=33)。
  • 胚胎培养4天(小鼠)或6.5天(人类),通过免疫荧光和二代测序评估编辑效果。

主要发现

  • 小鼠S期注射组95%胚胎存在基因修饰,其中89.47%完全编辑;M期注射组100%存在修饰,84.21%完全编辑。
  • 小鼠S期注射组仅46.88%到达囊胚,M期组19.05%,显著低于对照组S期90.24%和M期86.36%。
  • 人类M期注射IVM卵母细胞后88.37%的POU5F1靶向胚胎成功编辑,但仅4.55%到达晚期囊胚,且完全无ICM、滋养外胚层不规则。
  • 小鼠和人类中POU5F1缺失均导致SOX17表达缺失。
  • 部分人类靶向胚胎(38个中的9个)嵌合体被消除,其中3个发育为囊胚。

关键数值与推荐

  • 小鼠S期注射完全编辑率89.47%,M期84.21%;人类M期注射编辑效率88.37%。
  • 小鼠囊胚形成率:S期注射组46.88%,M期组19.05%,对照S期90.24%,对照M期86.36%。
  • 人类微注射胚胎晚期囊胚形成率4.55%。

临床怎么用

  • 研究提示POU5F1对植入前胚胎发育至关重要,敲除导致囊胚形成失败,可作为胚胎发育研究的参考。
  • 人类IVM卵母细胞CRISPR编辑效率高但发育潜能严重受损,需谨慎解释表型。
  • 减少嵌合体可能有助于更准确分析基因功能。

局限性

  • CRISPR-Cas9种系编辑的主要障碍是嵌合体,可能混淆表型分析和发育行为解读。
  • 研究使用废弃IVM人类卵母细胞,可能不能完全反映体内成熟卵母细胞的发育行为。
  • 小鼠与人类发育能力的比较可能受所选小鼠品系影响。
  • CRISPR-Cas9靶向效率存在变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the role of POU class 5 homeobox 1 (POU5F1) in human preimplantation development and how does it compare with the mouse model? SUMMARY ANSWER: POU5F1 is required for successful development of mouse and human embryos to the blastocyst stage as knockout embryos exhibited a significantly lower blastocyst formation rate, accompanied by lack of inner cell mass (ICM) formation. WHAT IS KNOWN ALREADY: Clustered regularly interspaced short palindromic repeats-CRISPR associated genes (CRISPR-Cas9) has previously been used to examine the role of POU5F1 during human preimplantation development. The reported POU5F1-targeted blastocysts always retained POU5F1 expression in at least one cell, because of incomplete CRISPR-Cas9 editing. The question remains of whether the inability to obtain fully edited POU5F1-targeted blastocysts in human results from incomplete editing or the actual inability of these embryos to reach the blastocyst stage. STUDY DESIGN, SIZE, DURATION: The efficiency of CRISPR-Cas9 to induce targeted gene mutations was first optimized in the mouse model. Two CRISPR-Cas9 delivery methods were compared in the B6D2F1 strain: S-phase injection (zygote stage) (n = 135) versus metaphase II-phase (M-phase) injection (oocyte stage) (n = 23). Four control groups were included: non-injected media-control zygotes (n = 43)/oocytes (n = 48); sham-injected zygotes (n = 45)/oocytes (n = 47); Cas9-protein injected zygotes (n = 23); and Cas9 protein and scrambled guide RNA (gRNA)-injected zygotes (n = 27). Immunofluorescence analysis was performed in Pou5f1-targeted zygotes (n = 37), media control zygotes (n = 19), and sham-injected zygotes (n = 15). To assess the capacity of Pou5f1-null embryos to develop further in vitro, additional groups of Pou5f1-targeted zygotes (n = 29) and media control zygotes (n = 30) were cultured to postimplantation stages (8.5 dpf). Aiming to identify differences in developmental capacity of Pou5f1-null embryos attributed to strain variation, zygotes from a second mouse strain-B6CBA (n = 52) were targeted. Overall, the optimized methodology was applied in human oocytes following IVM (metaphase II stage) (n = 101). The control group consisted of intracytoplasmically sperm injected (ICSI) IVM oocytes (n = 33). Immunofluorescence analysis was performed in human CRISPR-injected (n = 10) and media control (n = 9) human embryos. PARTICIPANTS/MATERIALS, SETTING, METHODS: A gRNA-Cas9 protein mixture targeting exon 2 of Pou5f1/POU5F1 was microinjected in mouse oocytes/zygotes or human IVM oocytes. Reconstructed embryos were cultured for 4 days (mouse) or 6.5 days (human) in sequential culture media. An additional group of mouse-targeted zygotes was cultured to postimplantation stages. Embryonic development was assessed daily, with detailed scoring at late blastocyst stage. Genomic editing was assessed by immunofluorescence analysis and next-generation sequencing. MAIN RESULTS AND THE ROLE OF CHANCE: Genomic analysis in mouse revealed very high editing efficiencies with 95% of the S-Phase and 100% of the M-Phase embryos containing genetic modifications, of which 89.47% in the S-Phase and 84.21% in the M-Phase group were fully edited. The developmental capacity was significantly compromised as only 46.88% embryos in the S-Phase and 19.05% in the M-Phase group reached the blastocyst stage, compared to 86.36% in control M-Phase and 90.24% in control S-Phase groups, respectively. Immunofluorescence analysis confirmed the loss of Pou5f1 expression and downregulation of the primitive marker SRY-Box transcription factor (Sox17). Our experiments confirmed the requirement of Pou5f1 expression for blastocyst development in the second B6CBA strain. Altogether, our data obtained in mouse reveal that Pou5f1 expression is essential for development to the blastocyst stage. M-Phase injection in human IVM oocytes (n = 101) similarly resulted in 88.37% of the POU5F1-targeted embryos being successfully edited. The developmental capacity of generated embryos was compromised from the eight-cell stage onwards. Only 4.55% of the microinjected embryos reached the late blastocyst stage and the embryos exhibited complete absence of ICM and an irregular trophectoderm cell layer. Loss of POU5F1 expression resulted in absence of SOX17 expression, as in mouse. Interestingly, genetic mosaicism was eliminated in a subset of targeted human embryos (9 out of 38), three of which developed into blastocysts. LIMITATIONS, REASONS FOR CAUTION: One of the major hurdles of CRISPR-Cas9 germline genome editing is the occurrence of mosaicism, which may complicate phenotypic analysis and interpretation of developmental behavior of the injected embryos. Furthermore, in this study, spare IVM human oocytes were used, which may not recapitulate the developmental behavior of in vivo matured oocytes. WIDER IMPLICATIONS OF THE FINDINGS: Comparison of developmental competency following CRISPR-Cas-mediated gene targeting in mouse and human may be influenced by the selected mouse strain. Gene targeting by CRISPR-Cas9 is subject to variable targeting efficiencies. Therefore, striving to reduce mosaicism can provide novel molecular insights into mouse and human embryogenesis. STUDY FUNDING/COMPETING INTEREST(S): The research was funded by the Ghent University Hospital and Ghent University and supported by the FWO-Vlaanderen (Flemish fund for scientific research, Grant no. G051516N), and Hercules funding (FWO.HMZ.2016.00.02.01). The authors declare no competing interests. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Stamatiadis P, Boel A, Cosemans G, et al. Comparative analysis of mouse and human preimplantation development following POU5F1 CRISPR/Cas9 targeting reveals interspecies differences. Hum Reprod. 2021. PMID: 33609360. doi:10.1093/humrep/deab027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。